Join Growin Stock Community!

Stereotaxis, inc.STXS.US Overview

US StockHealthcare
(No presentation for STXS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

STXS AI Insights

STXS Overall Performance

STXS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

STXS Recent Performance

1.16%

Stereotaxis, inc.

0.05%

Avg of Sector

-0.31%

S&P500

STXS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

STXS Key Information

STXS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

STXS Profile

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

Price of STXS

STXS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

STXS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.25
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
6.70
PB Ratio
32.92
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
53.07%
Net Margin
-78.56%
Revenue Growth (YoY)
19.61%
Profit Growth (YoY)
13.06%
3-Year Revenue Growth
-0.85%
3-Year Profit Growth
-3.52%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.25
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
6.70
PB Ratio
32.92
Price-to-FCF
-
Gross Margin
53.07%
Net Margin
-78.56%
Revenue Growth (YoY)
19.61%
Profit Growth (YoY)
13.06%
3-Year Revenue Growth
-0.85%
3-Year Profit Growth
-3.52%

  • When is STXS's latest earnings report released?

    The most recent financial report for Stereotaxis, inc. (STXS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating STXS's short-term business performance and financial health. For the latest updates on STXS's earnings releases, visit this page regularly.

  • What is the operating profit of STXS?

    According to the latest financial report, Stereotaxis, inc. (STXS) reported an Operating Profit of -6.56M with an Operating Margin of -87.85% this period, representing a decline of 3.34% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is STXS's revenue growth?

    In the latest financial report, Stereotaxis, inc. (STXS) announced revenue of 7.46M, with a Year-Over-Year growth rate of -18.83%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does STXS have?

    As of the end of the reporting period, Stereotaxis, inc. (STXS) had total debt of 5.58M, with a debt ratio of 0.12. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does STXS have?

    At the end of the period, Stereotaxis, inc. (STXS) held Total Cash and Cash Equivalents of 10.51M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does STXS go with three margins increasing?

    In the latest report, Stereotaxis, inc. (STXS) did not achieve the “three margins increasing” benchmark, with a gross margin of 54.9%%, operating margin of -87.85%%, and net margin of -90.9%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess STXS's profit trajectory and future growth potential.

  • Is STXS's EPS continuing to grow?

    According to the past four quarterly reports, Stereotaxis, inc. (STXS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of STXS?

    Stereotaxis, inc. (STXS)'s Free Cash Flow (FCF) for the period is -4.2M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 3.11% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of STXS?

    The latest valuation data shows Stereotaxis, inc. (STXS) has a Price-To-Earnings (PE) ratio of -9.11 and a Price/Earnings-To-Growth (PEG) ratio of -0.22. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.